Tatsuya Suwabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tatsuya Suwabe has a total of 416 co-authors. Here are the top co-authors by number of shared publications:
- Yoshifumi Ubara
Nephrology Center and the Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan
38 shared publications - Junichi Hoshino
Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan
31 shared publications - Naoki Sawa
Nephrology Center and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Minato, Tokyo, Japan
27 shared publications Eiko Hasegawa
Affiliation Department of Nephrology, Toranomon Hospital, Tokyo, Japan
24 shared publicationsNoriko Hayami
Department of Nephrology, Toranomon Hospital Kajigaya, Japan
22 shared publications- Masayuki Yamanouchi
Nephrology Center, Toranomon Hospital, Tokyo, Japan
18 shared publications
Latest Publications
- Open Access
- 12 February 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Ultrasound-guided lateral kidney biopsy in patients unsuitable for the prone position
Background: Kidney biopsy is the gold standard diagnostic technique for nephrologists. Appropriate patient positioning facilitates physiological stability and access to target anatomy. Factors such as patient weight, size and medical history, including respiratory or circulatory disorders, should guide position selection. However, most kidney biopsies are performed exclusively in the prone position and procedures are often deferred when this is not feasible. Although lateral kidney biopsy has been reported, it remains uncommon and its applications are not well established. We aimed to demonstrate the safety and utility of lateral kidney biopsies. Methods: We retrospectively reviewed patients who underwent lateral kidney biopsy at Toranomon Hospital Kajigaya between October 2015 and February 2025. Vital signs and blood test results pre- and post-biopsy were analysed. Results: Twenty-five patients underwent lateral kidney biopsies; six had abdominal aortic aneurysms (AAAs), 12 had respiratory distress (7 with massive ascites or pleural effusions, 2 with obesity, 2 with organomegaly and 1 with pericardial effusion), 6 had major joint pain (4 thin, 1 with scoliosis and 1 with arthritis) and 1 had stoma. All patients were histologically diagnosed and received appropriate treatment. Vital signs remained stable and only one patient with splenomegaly experienced a bleeding complication, which was not readily predictable and unlikely related to biopsy position. Conclusions: Lateral kidney biopsy offers a viable alternative for the accurate diagnosis of kidney diseases in patients in whom the prone position is challenging, including those with AAA, anasarca-induced respiratory distress or significant joint pain due to body habitus.
- 12 February 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Open AccessUltrasound-guided lateral kidney biopsy in patients unsuitable for the prone position
Background: Kidney biopsy is the gold standard diagnostic technique for nephrologists. Appropriate patient positioning facilitates physiological stability and access to target anatomy. Factors such as patient weight, size and medical history, including respiratory or circulatory disorders, should guide position selection. However, most kidney biopsies are performed exclusively in the prone position and procedures are often deferred when this is not feasible. Although lateral kidney biopsy has been reported, it remains uncommon and its applications are not well established. We aimed to demonstrate the safety and utility of lateral kidney biopsies. Methods: We retrospectively reviewed patients who underwent lateral kidney biopsy at Toranomon Hospital Kajigaya between October 2015 and February 2025. Vital signs and blood test results pre- and post-biopsy were analysed. Results: Twenty-five patients underwent lateral kidney biopsies; six had abdominal aortic aneurysms (AAAs), 12 had respiratory distress (7 with massive ascites or pleural effusions, 2 with obesity, 2 with organomegaly and 1 with pericardial effusion), 6 had major joint pain (4 thin, 1 with scoliosis and 1 with arthritis) and 1 had stoma. All patients were histologically diagnosed and received appropriate treatment. Vital signs remained stable and only one patient with splenomegaly experienced a bleeding complication, which was not readily predictable and unlikely related to biopsy position. Conclusions: Lateral kidney biopsy offers a viable alternative for the accurate diagnosis of kidney diseases in patients in whom the prone position is challenging, including those with AAA, anasarca-induced respiratory distress or significant joint pain due to body habitus.
- Open Access
- 5 December 2025
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 12 (4) , 1-2
Long-Term Effect and Safety of Tocilizumab on Severe Adult-Onset Still’s Disease Accompanied by Thrombotic Thrombocytopenic Purpura
Cite this article as: Suwabe T, Yamanouchi M, Ubara Y, Sawa N. Long-term effect and safety of tocilizumab on severe adult-onset Still’s disease accompanied by thrombotic thrombocytopenic purpura. Eur J Rheumatol. 2025, 12(4), 0029, doi: 10.5152/eurjrheum.2025.25029.
- 5 December 2025
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 12 (4) , 1-2
Open AccessLong-Term Effect and Safety of Tocilizumab on Severe Adult-Onset Still’s Disease Accompanied by Thrombotic Thrombocytopenic Purpura
Cite this article as: Suwabe T, Yamanouchi M, Ubara Y, Sawa N. Long-term effect and safety of tocilizumab on severe adult-onset Still’s disease accompanied by thrombotic thrombocytopenic purpura. Eur J Rheumatol. 2025, 12(4), 0029, doi: 10.5152/eurjrheum.2025.25029.
- Open Access
- 21 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0328133
Brachial-ankle pulse wave velocity predicts liver volume in patients with autosomal dominant polycystic kidney disease
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and Polycystic liver disease (PLD) is the most common extrarenal manifestation of ADPKD. Various non-inherited factors have been reported to affect total kidney volume (TKV) in ADPKD. However, the non-inherited factors affecting liver volume (LV) in ADPKD are unknown. Methods: We aimed to identify the factors affecting LV and TKV in ADPKD; and to analyze the relationship between changes in these parameters and arterial stiffness, assessed using brachial-ankle pulse wave velocity (baPWV). Results: We enrolled 165 patients (66 men and 99 women; mean age 47.3 ± 6.9 years). Univariable analysis revealed that sex, mean baPWV, ΔbaPWV, tolvaptan use, hyperlipidemia, hyperuricemia, Hb concentration, eGFR, proteinuria, and height-adjusted TKV (htTKV) were significantly associated with height-adjusted LV (htLV) at baseline. Multivariate analysis showed that sex, BMI, ΔbaPWV, and tolvaptan use were significantly associated with htLV at baseline. The baseline htLV correlated with ΔbaPWV (r = 0.32, p < 0.0001). Univariable linear mixed model analysis revealed that sex, mean baPWV, ΔbaPWV, tolvaptan use, hyperuricemia, Hb concentration, eGFR, and proteinuria significantly affected the change in htLV. Multivariate linear mixed model analysis revealed that sex, BMI, and tolvaptan use significantly affected the change in htLV. The change in the htLV ratio was larger in patients with a higher ΔbaPWV (p < 0.0001). Whereas, ΔbaPWV was not a significant factor for the baseline htTKV and the changes in htTKV in univariable and multivariable analysis. Conclusions: We have shown that ΔbaPWV is a predictor of baseline htLV, and the chronological changes in htLV in patients with ADPKD.
- 21 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0328133
Open AccessBrachial-ankle pulse wave velocity predicts liver volume in patients with autosomal dominant polycystic kidney disease
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and Polycystic liver disease (PLD) is the most common extrarenal manifestation of ADPKD. Various non-inherited factors have been reported to affect total kidney volume (TKV) in ADPKD. However, the non-inherited factors affecting liver volume (LV) in ADPKD are unknown. Methods: We aimed to identify the factors affecting LV and TKV in ADPKD; and to analyze the relationship between changes in these parameters and arterial stiffness, assessed using brachial-ankle pulse wave velocity (baPWV). Results: We enrolled 165 patients (66 men and 99 women; mean age 47.3 ± 6.9 years). Univariable analysis revealed that sex, mean baPWV, ΔbaPWV, tolvaptan use, hyperlipidemia, hyperuricemia, Hb concentration, eGFR, proteinuria, and height-adjusted TKV (htTKV) were significantly associated with height-adjusted LV (htLV) at baseline. Multivariate analysis showed that sex, BMI, ΔbaPWV, and tolvaptan use were significantly associated with htLV at baseline. The baseline htLV correlated with ΔbaPWV (r = 0.32, p < 0.0001). Univariable linear mixed model analysis revealed that sex, mean baPWV, ΔbaPWV, tolvaptan use, hyperuricemia, Hb concentration, eGFR, and proteinuria significantly affected the change in htLV. Multivariate linear mixed model analysis revealed that sex, BMI, and tolvaptan use significantly affected the change in htLV. The change in the htLV ratio was larger in patients with a higher ΔbaPWV (p < 0.0001). Whereas, ΔbaPWV was not a significant factor for the baseline htTKV and the changes in htTKV in univariable and multivariable analysis. Conclusions: We have shown that ΔbaPWV is a predictor of baseline htLV, and the chronological changes in htLV in patients with ADPKD.
- Open Access
- 20 May 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (9) , 1535-1550
Association Between Body Mass Index and Age at End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease in the United States and Japan
- 20 May 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (9) , 1535-1550
Open AccessAssociation Between Body Mass Index and Age at End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease in the United States and Japan
- 25 January 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3396-3404
Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease
Objectives: To evaluate the efficacy and safety of first-line targeted synthetic DMARDs (tsDMARDs) in patients with RA and chronic kidney disease (CKD). Methods: This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed. The patients were categorized by kidney function and tsDMARD modality. The primary outcome was the 24-month drug retention rate, and the secondary outcomes were changes in the Disease Activity Score 28-CRP (DAS28-CRP) level, prednisolone dosage and reasons for discontinuation. Results: The 24-month drug retention rates according to the estimated glomerular filtration rate (eGFR) (≥60%, 30–60% or <30 ml/min/1.73 m2) were as follows: all tsDMARDs (46.0%, 44.1%, 47.1%), tofacitinib (55.9%, 53.3%, 66.7%), baricitinib (64.2%, 42.0%) and peficitinib (36.4%, 44.1%, 40.0%). Even in groups with lower kidney function, the drug retention rate was maintained (adjusted hazard ratio was 1.14 [95% confidence interval, 0.81–1.62], P = 0.45). Patients had a decreased DAS28-CRP (P < 0.01) and a reduced prednisolone dosage (P < 0.01) over the six-month period following tsDMARD initiation. The incidence of herpes zoster and deep vein thrombosis (DVT) was higher in the group with an eGFR <30 ml/min/1.73 m2, but not statistically significant. Conclusions: tsDMARDs have demonstrated efficacy and safety in patients with RA and CKD; however, clinicians should consider the potential for herpes zoster and DVT in patients with eGFR <30 ml/min/1.73 m2.
- 25 January 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3396-3404
Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease
Objectives: To evaluate the efficacy and safety of first-line targeted synthetic DMARDs (tsDMARDs) in patients with RA and chronic kidney disease (CKD). Methods: This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed. The patients were categorized by kidney function and tsDMARD modality. The primary outcome was the 24-month drug retention rate, and the secondary outcomes were changes in the Disease Activity Score 28-CRP (DAS28-CRP) level, prednisolone dosage and reasons for discontinuation. Results: The 24-month drug retention rates according to the estimated glomerular filtration rate (eGFR) (≥60%, 30–60% or <30 ml/min/1.73 m2) were as follows: all tsDMARDs (46.0%, 44.1%, 47.1%), tofacitinib (55.9%, 53.3%, 66.7%), baricitinib (64.2%, 42.0%) and peficitinib (36.4%, 44.1%, 40.0%). Even in groups with lower kidney function, the drug retention rate was maintained (adjusted hazard ratio was 1.14 [95% confidence interval, 0.81–1.62], P = 0.45). Patients had a decreased DAS28-CRP (P < 0.01) and a reduced prednisolone dosage (P < 0.01) over the six-month period following tsDMARD initiation. The incidence of herpes zoster and deep vein thrombosis (DVT) was higher in the group with an eGFR <30 ml/min/1.73 m2, but not statistically significant. Conclusions: tsDMARDs have demonstrated efficacy and safety in patients with RA and CKD; however, clinicians should consider the potential for herpes zoster and DVT in patients with eGFR <30 ml/min/1.73 m2.
- Open Access
- 4 July 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (10) , 1278-1287
Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
Objective To evaluate the efficacy and safety of first-line biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) with chronic kidney disease (CKD), including those undergoing haemodialysis (HD). Methods This retrospective cohort study included 425 patients with RA prescribed their first bDMARDs at two hospitals from 2004 to 2021. Patients were categorised by kidney function and bDMARD modality (TNFα inhibitors (TNFαis), interleukin-6 inhibitors (IL-6is), cytotoxic T-lymphocyte antigen-4 immunoglobulin (CTLA4-Ig)). The primary outcome was the 36-month drug retention rate, with secondary outcomes including changes in Disease Activity Score 28 (DAS28)-C reactive protein (CRP)/erythrocyte sedimentation rate (ESR), prednisolone dosage and reasons for discontinuation. Results The 36-month drug retention rates by estimated glomerular filtration rate (eGFR) (≥60, 30–60, 2) were as follows: all bDMARDs (45.2%, 32.0%, 41.4%), TNFαis (45.3%, 28.2%, 34.0%), IL-6is (47.4%, 66.7%, 71.4%) and CTLA-4Ig (50.0%, 31.3%, 33.3%). Even in groups with lower kidney function, the drug retention rate of bDMARDs was generally maintained. However, the retention rate of TNFαis was significantly lower in patients with eGFR 2. IL-6is showed the highest retention rate and the lowest discontinuation rate due to ineffectiveness in this group (HR 0.11, 95% CI 0.02 to 0.85, p=0.03). All bDMARDs improved DAS28-CRP/ESR and reduced prednisolone dosage across all groups. Conclusion bDMARDs demonstrated effective and safe profiles in patients with RA with CKD, even among patients on HD. In particular, IL-6is had a significantly higher drug retention rate in patients with an eGFR of 2 and fewer discontinuations due to ineffectiveness. IL-6is were more efficacious as monotherapy compared with the other bDMARDs.
- 4 July 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (10) , 1278-1287
Open AccessEfficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
Objective To evaluate the efficacy and safety of first-line biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) with chronic kidney disease (CKD), including those undergoing haemodialysis (HD). Methods This retrospective cohort study included 425 patients with RA prescribed their first bDMARDs at two hospitals from 2004 to 2021. Patients were categorised by kidney function and bDMARD modality (TNFα inhibitors (TNFαis), interleukin-6 inhibitors (IL-6is), cytotoxic T-lymphocyte antigen-4 immunoglobulin (CTLA4-Ig)). The primary outcome was the 36-month drug retention rate, with secondary outcomes including changes in Disease Activity Score 28 (DAS28)-C reactive protein (CRP)/erythrocyte sedimentation rate (ESR), prednisolone dosage and reasons for discontinuation. Results The 36-month drug retention rates by estimated glomerular filtration rate (eGFR) (≥60, 30–60, 2) were as follows: all bDMARDs (45.2%, 32.0%, 41.4%), TNFαis (45.3%, 28.2%, 34.0%), IL-6is (47.4%, 66.7%, 71.4%) and CTLA-4Ig (50.0%, 31.3%, 33.3%). Even in groups with lower kidney function, the drug retention rate of bDMARDs was generally maintained. However, the retention rate of TNFαis was significantly lower in patients with eGFR 2. IL-6is showed the highest retention rate and the lowest discontinuation rate due to ineffectiveness in this group (HR 0.11, 95% CI 0.02 to 0.85, p=0.03). All bDMARDs improved DAS28-CRP/ESR and reduced prednisolone dosage across all groups. Conclusion bDMARDs demonstrated effective and safe profiles in patients with RA with CKD, even among patients on HD. In particular, IL-6is had a significantly higher drug retention rate in patients with an eGFR of 2 and fewer discontinuations due to ineffectiveness. IL-6is were more efficacious as monotherapy compared with the other bDMARDs.
- Open Access
- 1 May 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (8) , 1106-1115
Genetic Analysis of Severe Polycystic Liver Disease in Japan
Key Points: Among patients with severe polycystic liver disease (PLD) (height-adjusted total liver volume of PKD2 variants were found in 34%. Three patients with PKD1 or PKD2 variants are reported with severe PLD but normal-sized kidneys (hTKV of < 250 ml/m). Background: Polycystic liver disease (PLD) is present in most patients with autosomal dominant polycystic kidney disease (ADPKD). PLD can alternatively be found with few, if any, kidney cysts as a diagnosis of isolated PLD (autosomal dominant PLD [ADPLD]). Several genes are identified as causative for this spectrum of phenotypes; however, the relative incidence of genetic etiologies among patients with severe PLD is unknown. Methods: Patients with ADPKD or ADPLD having severe PLD defined as height-adjusted total liver volume (hTLV) >1800 ml/m were recruited. Subsequent clinical care was followed. Genetic analysis was performed using whole exome sequencing. Results: We enrolled and sequenced 49 patients (38 women, 11 men). Pathogenic or suspected pathogenic variants in polycystic disease genes were found in 44 of 49 patients (90%). The disease gene was PKD1 in 20 of 44 patients (45%), PKD2 in 15 of 44 patients (34%), PRKCSH in 5 of 44 patients (11%), GANAB in 2 of 44 patients (5%), SEC63 in 1 of 44 patients (2%), and ALG8 in 1 of 44 patients (2%). The median hTLV was no different between genetically defined ADPKD and ADPLD groups (4431 [range, 1817–9148] versus 3437 [range, 1860–8211]) ml, P = 0.77), whereas height-adjusted kidney volume was larger as expected in ADPKD than in ADPLD (607 [range, 190–2842] versus 179 [range, 138–234] ml/m, P < 0.01). Of the clinically defined ADPKD patients, 20 of 38 patients (53%) were PKD1, 15 of 38 (39%) were PKD2, and 3 (8%) remained genetically unsolved. Among patients with a pathogenic PKD1 or PKD2 variant, we found three patients with a liver-dominant ADPKD (severe PLD with height-adjusted total kidney volume PKD2 carriers than in any previously reported ADPKD cohorts. Although there was no significant difference in the hTLV between patients with PKD1 and PKD2 in this cohort, our data suggest that enrollment on the basis of severe PLD may enrich for patients with PKD2.
- 1 May 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (8) , 1106-1115
Open AccessGenetic Analysis of Severe Polycystic Liver Disease in Japan
Key Points: Among patients with severe polycystic liver disease (PLD) (height-adjusted total liver volume of PKD2 variants were found in 34%. Three patients with PKD1 or PKD2 variants are reported with severe PLD but normal-sized kidneys (hTKV of < 250 ml/m). Background: Polycystic liver disease (PLD) is present in most patients with autosomal dominant polycystic kidney disease (ADPKD). PLD can alternatively be found with few, if any, kidney cysts as a diagnosis of isolated PLD (autosomal dominant PLD [ADPLD]). Several genes are identified as causative for this spectrum of phenotypes; however, the relative incidence of genetic etiologies among patients with severe PLD is unknown. Methods: Patients with ADPKD or ADPLD having severe PLD defined as height-adjusted total liver volume (hTLV) >1800 ml/m were recruited. Subsequent clinical care was followed. Genetic analysis was performed using whole exome sequencing. Results: We enrolled and sequenced 49 patients (38 women, 11 men). Pathogenic or suspected pathogenic variants in polycystic disease genes were found in 44 of 49 patients (90%). The disease gene was PKD1 in 20 of 44 patients (45%), PKD2 in 15 of 44 patients (34%), PRKCSH in 5 of 44 patients (11%), GANAB in 2 of 44 patients (5%), SEC63 in 1 of 44 patients (2%), and ALG8 in 1 of 44 patients (2%). The median hTLV was no different between genetically defined ADPKD and ADPLD groups (4431 [range, 1817–9148] versus 3437 [range, 1860–8211]) ml, P = 0.77), whereas height-adjusted kidney volume was larger as expected in ADPKD than in ADPLD (607 [range, 190–2842] versus 179 [range, 138–234] ml/m, P < 0.01). Of the clinically defined ADPKD patients, 20 of 38 patients (53%) were PKD1, 15 of 38 (39%) were PKD2, and 3 (8%) remained genetically unsolved. Among patients with a pathogenic PKD1 or PKD2 variant, we found three patients with a liver-dominant ADPKD (severe PLD with height-adjusted total kidney volume PKD2 carriers than in any previously reported ADPKD cohorts. Although there was no significant difference in the hTLV between patients with PKD1 and PKD2 in this cohort, our data suggest that enrollment on the basis of severe PLD may enrich for patients with PKD2.
- 8 February 2023
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (4) , 999-1010
Acute renal intracystic hemorrhage in patients with autosomal dominant polycystic kidney disease
Background Renal cyst bleeding is a frequent problem in patients with autosomal dominant polycystic kidney disease (ADPKD). However, information is still limited on its frequency, causative factors, and effects on enlargement of polycystic kidneys in ADPKD. Methods We investigated the total volume of acute renal intracystic hemorrhage and its association with total kidney volume (TKV) in a large series of patients with ADPKD on dialysis, referred for renal transcatheter arterial embolization. All patients had undergone CT scan and MRI scan before the procedure. We evaluated factors potentially associated with acute renal intracystic hemorrhage. The association between the volume of acute renal intracystic hemorrhage and the potential predisposing and associated factors was analysed by univariable and multivariable regressions. Results We enrolled 199 patients who underwent renal transcatheter arterial embolization from 2014 to 2018 (107 men, 92 women; mean age 59.1 ± 8.6 years). The median volume of acute renal intracystic hemorrhage was 97.3 ml (interquartile range 36.6–261.7 ml). Multivariable analysis revealed that body weight, kidney stones, systolic blood pressure, and total volume of acute renal intracystic hemorrhage were significantly associated with TKV; age, body mass index, smoking, renal cyst infection, serum alkaline phosphatase, and TKV were significantly associated with the volume of acute renal intracystic hemorrhage ; and sex, age, dialysis vintage, TKV, and total volume of acute renal intracystic hemorrhage were significantly associated with the number of microcoils required to achieve renal transcatheter arterial embolization. Total volume of acute renal intracystic hemorrhage was significantly associated with TKV (r = 0.15, p = 0.0325) and was greater in younger patients (r= − 0.32, p < 0.0001). Total volume of acute renal intracystic hemorrhage was also correlated with the number of microcoils required for renal transcatheter arterial embolization (r = 0.23, p = 0.0012). Conclusion Acute renal intracystic hemorrhage is frequent among ADPKD patients on dialysis, and total volume of acute renal intracystic hemorrhage significantly associated with TKV. Total volume of acute renal intracystic hemorrhage was greater in younger patients with higher renal artery luminal size. These results suggest that renal cyst bleeding and renal artery blood flow may synergistically accelerate the enlargement of polycystic kidneys in ADPKD patients on dialysis. Graphical abstract
- 8 February 2023
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (4) , 999-1010
Acute renal intracystic hemorrhage in patients with autosomal dominant polycystic kidney disease
Background Renal cyst bleeding is a frequent problem in patients with autosomal dominant polycystic kidney disease (ADPKD). However, information is still limited on its frequency, causative factors, and effects on enlargement of polycystic kidneys in ADPKD. Methods We investigated the total volume of acute renal intracystic hemorrhage and its association with total kidney volume (TKV) in a large series of patients with ADPKD on dialysis, referred for renal transcatheter arterial embolization. All patients had undergone CT scan and MRI scan before the procedure. We evaluated factors potentially associated with acute renal intracystic hemorrhage. The association between the volume of acute renal intracystic hemorrhage and the potential predisposing and associated factors was analysed by univariable and multivariable regressions. Results We enrolled 199 patients who underwent renal transcatheter arterial embolization from 2014 to 2018 (107 men, 92 women; mean age 59.1 ± 8.6 years). The median volume of acute renal intracystic hemorrhage was 97.3 ml (interquartile range 36.6–261.7 ml). Multivariable analysis revealed that body weight, kidney stones, systolic blood pressure, and total volume of acute renal intracystic hemorrhage were significantly associated with TKV; age, body mass index, smoking, renal cyst infection, serum alkaline phosphatase, and TKV were significantly associated with the volume of acute renal intracystic hemorrhage ; and sex, age, dialysis vintage, TKV, and total volume of acute renal intracystic hemorrhage were significantly associated with the number of microcoils required to achieve renal transcatheter arterial embolization. Total volume of acute renal intracystic hemorrhage was significantly associated with TKV (r = 0.15, p = 0.0325) and was greater in younger patients (r= − 0.32, p < 0.0001). Total volume of acute renal intracystic hemorrhage was also correlated with the number of microcoils required for renal transcatheter arterial embolization (r = 0.23, p = 0.0012). Conclusion Acute renal intracystic hemorrhage is frequent among ADPKD patients on dialysis, and total volume of acute renal intracystic hemorrhage significantly associated with TKV. Total volume of acute renal intracystic hemorrhage was greater in younger patients with higher renal artery luminal size. These results suggest that renal cyst bleeding and renal artery blood flow may synergistically accelerate the enlargement of polycystic kidneys in ADPKD patients on dialysis. Graphical abstract
- 27 December 2022
- Published by Springer Nature in CEN Case Reports
- Vol. 12 (3) , 304-310
Microbiome of infected cysts, feces and saliva in patients with autosomal dominant polycystic kidney disease
Cyst infection is a frequent and serious complication of autosomal dominant polycystic kidney disease (ADPKD). Hematogenous spread via bacterial translocation in the intestine is considered to be the main cause, so intestinal flora may be involved. However, the exact role of the intestinal flora in cyst infection in ADPKD is unknown. We report a 66-year-old woman and a 56-year-old man with ADPKD who had severe hepatic cyst infection. We analyzed the microbiome of infected cyst content, feces, and saliva in these two patients. The microbiome of patient 1 showed various bacteria in an infected cyst, whereas that of patient 2 showed only one bacterium. In both patients, the composition of the microbiome of the cyst content was quite different from those of feces and saliva, and the main bacteria in the infected cyst content represented a small proportion of those in feces and saliva. Lactobacilli were not almost detected in the infected cyst content though some lactobacilli are endemic in the gastrointestinal tract and the saliva. The association between bacteria in cysts and those in feces or saliva remains uncertain, and further research on this topic is needed.
- 27 December 2022
- Published by Springer Nature in CEN Case Reports
- Vol. 12 (3) , 304-310
Microbiome of infected cysts, feces and saliva in patients with autosomal dominant polycystic kidney disease
Cyst infection is a frequent and serious complication of autosomal dominant polycystic kidney disease (ADPKD). Hematogenous spread via bacterial translocation in the intestine is considered to be the main cause, so intestinal flora may be involved. However, the exact role of the intestinal flora in cyst infection in ADPKD is unknown. We report a 66-year-old woman and a 56-year-old man with ADPKD who had severe hepatic cyst infection. We analyzed the microbiome of infected cyst content, feces, and saliva in these two patients. The microbiome of patient 1 showed various bacteria in an infected cyst, whereas that of patient 2 showed only one bacterium. In both patients, the composition of the microbiome of the cyst content was quite different from those of feces and saliva, and the main bacteria in the infected cyst content represented a small proportion of those in feces and saliva. Lactobacilli were not almost detected in the infected cyst content though some lactobacilli are endemic in the gastrointestinal tract and the saliva. The association between bacteria in cysts and those in feces or saliva remains uncertain, and further research on this topic is needed.
- Open Access
- 3 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6528
Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in which family history is unclear, a differential diagnosis between ADPKD and other cystic kidney diseases is important. When diagnosing ADPKD, cystic kidney diseases that can easily be excluded using clinical information include: multiple simple renal cysts, acquired cystic kidney disease (ACKD), multilocular renal cyst/multilocular cystic nephroma/polycystic nephroma, multicystic kidney/multicystic dysplastic kidney (MCDK), and unilateral renal cystic disease (URCD). However, there are other cystic kidney diseases that usually require genetic testing, or another means of supplementing clinical information to enable a differential diagnosis of ADPKD. These include autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant tubulointerstitial kidney disease (ADTKD), nephronophthisis (NPH), oral-facial-digital (OFD) syndrome type 1, and neoplastic cystic kidney disease, such as tuberous sclerosis (TSC) and Von Hippel-Lindau (VHL) syndrome. To help physicians evaluate cystic kidney diseases, this article provides a review of cystic kidney diseases for which a differential diagnosis is required for ADPKD.
- 3 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6528
Open AccessCystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in which family history is unclear, a differential diagnosis between ADPKD and other cystic kidney diseases is important. When diagnosing ADPKD, cystic kidney diseases that can easily be excluded using clinical information include: multiple simple renal cysts, acquired cystic kidney disease (ACKD), multilocular renal cyst/multilocular cystic nephroma/polycystic nephroma, multicystic kidney/multicystic dysplastic kidney (MCDK), and unilateral renal cystic disease (URCD). However, there are other cystic kidney diseases that usually require genetic testing, or another means of supplementing clinical information to enable a differential diagnosis of ADPKD. These include autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant tubulointerstitial kidney disease (ADTKD), nephronophthisis (NPH), oral-facial-digital (OFD) syndrome type 1, and neoplastic cystic kidney disease, such as tuberous sclerosis (TSC) and Von Hippel-Lindau (VHL) syndrome. To help physicians evaluate cystic kidney diseases, this article provides a review of cystic kidney diseases for which a differential diagnosis is required for ADPKD.